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Abstract
Objective:  The  aim  of  this  study  was  to  compare  two  different  empiric  treatments  for  late-
onset neonatal  sepsis,  vancomycin  and  oxacillin,  in  a  neonatal  intensive  care  unit  with  a  high
prevalence of  coagulase-negative  Staphylococcus.
Methods:  A  cross-sectional  study  was  conducted  in  an  neonatal  intensive  care  unit  from  2011
to 2014.  Data  from  the  medical  records  of  at-risk  newborns  were  collected  daily.  Infections
were deﬁned  according  to  the  National  Health  Surveillance  Agency  criteria.  Data  analysis  was
performed  using  an  internal  program.
Results:  There  was  a  signiﬁcant  reduction  in  the  number  of  Staphylococcus  aureus  infections
(p =  0.008),  without  endocarditis,  meningitis,  or  lower  respiratory  tract  infection,  as  well  as
a reduction  in  the  frequency  of  deaths  related  to  S.  aureus  infection.  There  were  no  signiﬁ-
cant changes  in  the  incidence  of  Gram-negative  bacterial  or  fungal  infections.  An  increase  in
coagulase-negative  Staphylococcus  infections  was  observed  (p  =  0.022).  However,  there  was  no
 Please cite this article as: Romanelli RM, Anchieta LM, Silva AC, de Jesus LA, Rosado V, Clemente WT. Empirical antimicrobial therapy
or late-onset sepsis in a neonatal unit with high prevalence of coagulase-negative Staphylococcus.  J Pediatr (Rio J). 2016;92:472--8.
 Study conducted at Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
∗ Corresponding author.
E-mail: rmcromanelli@gmail.com (R.M.C. Romanelli).
ttp://dx.doi.org/10.1016/j.jped.2016.01.008
021-7557/© 2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Empirical  therapy  for  neonatal  late-onset  sepsis  473
measured  increase  in  related  morbidity  and  mortality.  There  was  a  reduction  in  the  median
number of  days  of  treatment  with  oxacillin  from  11.5  to  6  days  (p  <  0.001)  and  an  increase  of
one day  in  the  median  number  of  days  of  treatment  with  vancomycin  (p  =  0.046).
Conclusions:  Modiﬁcation  of  the  empiric  treatment  regimen  for  neonatal  late-onset  sepsis  with
use of  oxacillin  showed  a  signiﬁcant  reduction  in  S.  aureus  infections,  as  well  as  a  reduction  in
the frequency  of  infections  with  major  organ  system  involvement  and  mortality  due  to  infection
with this  microorganism.  As  a  result,  oxacillin  can  be  considered  as  an  effective  treatment  for
late-onset  sepsis,  making  it  possible  to  avoid  broad-spectrum  antibiotics.
© 2016  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Sociedade  Brasileira  de  Pediatria.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Terapia  antimicrobiana  empírica  para  sepse  tardia  na  unidade  neonatal  com  alta
prevalência  de  Staphylococcus  coagulase  negativo
Resumo
Objetivo:  Comparar  dois  períodos  com  diferentes  esquemas  empíricos  para  tratamento  de
sepse neonatal  tardia,  incluindo  vancomicina  ou  oxacilina  respectivamente,  em  Unidade  Neona-
tal de  referência  com  alta  prevalência  de  Staphylococcus  coagulase  negativo.
Métodos:  Estudo  transversal,  realizado  em  Unidade  Neonatal  de  referência,  de  2011  a  2014.  A
coleta de  dados  foi  realizada  diariamente  por  vigilância  ativa  em  prontuário  de  recém-nascidos
de risco.  As  infecc¸ões  foram  notiﬁcadas  conforme  critérios  deﬁnidos  pela  Agência  Nacional  de
Vigilância Sanitária.  O  banco  de  dados  e  a  análise  foram  realizados  em  programa  interno.
Resultados:  Ocorreu  reduc¸ão  signiﬁcativa  da  notiﬁcac¸ão  de  infecc¸ões  por  Staphylococcus
aureus (p  =  0,008),  sem  notiﬁcac¸ões  de  endocardite,  meningite  e  infecc¸ões  de  vias  aéreas
inferiores,  além  de  reduc¸ão  na  frequência  de  óbitos  pelo  micro-organismo  e  sem  alterac¸ão  sig-
niﬁcativa  nas  incidências  de  infecc¸ões  por  bactérias  Gram  negativas  e  fungos.  Houve  aumento
de infecc¸ões  S.  coagulase  negativo  (p  =  0,022),  mas  sem  aumento  de  morbidade  e  mortalidade.
Ocorreu  reduc¸ão  na  mediana  do  tempo  de  uso  de  oxacilina,  de  11,5  para  6  dias  (p  <  0,001),  com
aumento de  mediana  de  um  dia  de  uso  de  vancomicina  (p  =  0,046).
Conclusões:  A  modiﬁcac¸ão  do  esquema  empírico  com  utilizac¸ão  de  oxacilina  revelou  reduc¸ão
signiﬁcativa  das  infecc¸ões  por  S.  aureus,  além  da  reduc¸ão  na  frequência  de  infecc¸ão  de  foco
profundo  e  mortalidade  pelo  micro-organismo.  Considera-se  que  oxacilina  pode  ser  utilizada
como esquema  de  tratamento  de  sepse  neonatal  tardia,  evitando-se  o  uso  de  antibióticos  de
largo espectro.
©  2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Sociedade  Brasileira  de  Pediatria.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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The  most  prevalent  microorganisms  in  late-onset  neonatal
sepsis  described  in  international  literature  are  coagulase-
negative  Staphylococcus  (CoNS).1--6 While  rates  of
laboratory-conﬁrmed  sepsis  due  to  these  microorgan-
isms  vary  from  30%  to  60%,1 higher  rates  have  also  been
reported.  These  microorganisms  account  for  77.9%  of
late-onset  neonatal  sepsis  in  industrialized  countries  and
46.5%  in  developing  regions.2 However,  infections  caused  by
these  commensal  microorganisms  are  often  questioned  due
to  difﬁculties  in  conﬁrmation  and  differences  in  notiﬁcation
criteria.1,7
It  should  also  be  considered  that  CoNS  are  minimally  inva-
sive  microorganisms  that  colonize  infants  after  birth  and  are
normally  present  in  the  microbiomes  of  different  body  sites.
They  have  the  beneﬁcial  effect  of  stimulating  the  innate
immune  response  and  improving  the  defense  against  other
pathogens.2 However,  defense  mechanisms  can  be  inade-
quate  in  newborn  infants,  increasing  their  susceptibility  to
M
T
Hnfection  by  these  microorganisms.3 On  the  other  hand,
lthough  they  are  considered  to  be  microorganisms  respon-
ible  for  sepsis  in  newborn  infants,  they  present  insidious
volution  and  low  morbidity  and  mortality.2,5,8--11
It  is  known  that  the  resistance  proﬁle  of  CoNS  can
xceed  90%  for  isoxazolyl  penicillin.3 As  a  result,  vancomycin
as  been  considered  the  standard  treatment.1,12 However,
ancomycin  restriction  as  empiric  therapy  for  late-onset
eonatal  sepsis  has  been  indicated  in  literature.9--11,13
The  objective  of  this  study  was  to  compare,  epidemi-
logically,  two  different  empiric  treatments  for  late-onset
epsis  in  a  neonatal  intensive  care  unit  (NICU)  with  a  high
revalence  of  CoNS  and  oxacillin-sensitive  Staphylococcus
ureus.ethods
his  observational  prospective  study  was  conducted  at
ospital  das  Clínicas,  at  the  Federal  University  of  Minas
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erais  (HC/UFMG),  from  January  2011  to  December  2014.
C/UFMG,  a  university  hospital,  is  a  resource  for  managing
igh  obstetric  risk  in  Belo  Horizonte  and  in  the  state  of  Minas
erais.
The  target  population  consisted  of  all  newborn  infants
n  the  NICU  considered  at  risk  for  late-onset  sepsis.  Risk
actors  included  weight  under  1500  g,  presence  of  a  central
enous  catheter  (CVC),  use  of  mechanical  ventilation  (MV),
urgery,  and  treatment  with  antimicrobial  agents.  These
t-risk  infants  were  followed  daily  by  specialized  Hospital
nfection  Control  Commission  (HICC)  staff.  Data  were  col-
ected  by  active  surveillance,  review  of  medical  records,
nd  discussion  with  the  care  team.  Infections  were  reported
ccording  to  the  national  legislation,14 with  infection  crite-
ia  deﬁned  by  the  Agência  Nacional  de  Vigilância  Sanitária
ANVISA),15 based  on  the  National  Healthcare  Safety  Net-
ork  (NHSN).7,16
The  inclusion  criteria  considered  all  newborn  infants
reated  with  oxacillin  or  vancomycin  as  empiric  treatment
or  late-onset  sepsis,  reported  after  48  h  of  life,  as  deﬁned
y  ANVISA.15 ‘‘Sepsis’’  and  ‘‘bloodstream  infection’’  were
sed  synonymously.
A  sample  size  was  calculated  considering  the  prevalence
f  laboratory-conﬁrmed  CoNS  and  S.  aureus  infections  at  a
ate  of  almost  30%  and  15%  respectively,  based  on  a  popula-
ion  of  300  patients  at  risk  per  year.
An  internal  program  of  HICC  was  used  for  statistical
nalysis.  Descriptive  analysis  included  frequency  of  at-risk
atients,  frequency  of  patients  with  hospital-associated
nfections  (HAI),  frequency  of  HAI,  cumulative  incidence  of
AI  (number  of  HAI  per  100  patients  at  risk)  and  HAI  inci-
ence  density  (number  of  HAI  per  1000  patient-days).  The
ncidence  density  of  HAI  was  also  stratiﬁed  according  to
eight  range  and  topography  of  infection.  Density  of  infec-
ion  of  device-associated  infections  was  measured,  including
nfections  associated  to  CVC,  MV,  and  indwelling  urethral
atheter  (IUC).
The  frequency  of  microorganisms  has  been  described
n  groups  (CoNS,  S.  aureus, gram-negative  bacteria  and
ungi)  and  by  frequency  of  antimicrobial  agents  used  for
mpiric  or  speciﬁc  Staphylococcus  spp.  coverage  (oxacillin
nd  vancomycin).  In  general,  these  antimicrobial  agents  are
mpirically  or  speciﬁcally  used  for  treatment  of  infection
ith  Staphylococcus  spp.  Other  antimicrobial  agents  were
ot  described,  as  they  are  not  relevant  to  this  study.
Microbiological  isolation  in  patient  samples  was  per-
ormed  by  automated  method  (VITEK®2,  BioMérieux  Inc,
h
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i
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Table  1  Incidence  densitya of  healthcare-associated  infections  b
2011--2014.
Weight  (g)  Total  Period  1  P
(2011--2014)  (2011--2012)  (2
<750  27.01  26.67  2
751--1000 24.02  26.37  2
1001--1500 19.57  18.88  2
1501--2500 25.59  29.76  2
>2500 19.18  20.56  1
Total 22.20  24.21  2
a Number of infections per 1000 patient-days.Romanelli  RM  et  al.
SA)  and  susceptibility  testing  by  disk  diffusion  agar
Kirby--Bauer).  The  sensitivity  proﬁle  of  microorganisms  was
eﬁned  according  to  the  hospital’s  HICC  and  based  on  the
linical  and  Laboratory  Standards  Institute  (CLSI).
For  comparative  analysis,  two  periods  were  deﬁned:  Jan-
ary  2011  to  December  2012  (Period  1)  and  January  2013  to
ecember  2014  (Period  2).  During  Period  1,  vancomycin  was
sed  in  the  empiric  treatment  regimen  for  late-onset  sepsis,
hile  oxacillin  was  used  during  Period  2.
Mortality  (deaths  over  total  number  of  patients  at  risk)
nd  lethality  (deaths  over  total  number  of  patients  with
AI),  considering  CoNS  or  S.  aureus,  were  compared  in  both
eriods.  Death  was  considered  associated  with  infection  if
t  occurred  during  or  within  15  days  of  treatment  with  the
tudy  antibiotic.
Morbidity  was  deﬁned  as  infection  with  major  organ  sys-
em  involvement  such  as  endocarditis,  lower  respiratory
ract  infection  (pneumonia  or  tracheal  or  bronchial  infec-
ion),  or  central  nervous  system  infection  with  isolation  of
hese  microorganisms,  as  well  as  number  of  days  of  antimi-
robial  treatment  with  oxacillin  or  vancomycin.
Statistical  analysis  was  performed  by  a  statistician  using
PSS® (SPSS  Inc.,  version  15.0,  USA)  and  EpiInfo® v.  7.0  (CDC,
SA).  Descriptive  analysis  included  frequency,  percentage,
ean,  standard  deviation,  median  and  range.  Comparative
nalysis  was  performed  using  X2 or  Fisher  test  for  categori-
al  variables  and  Student’s  t-test  or  the  Mann--Whitney  test
or  quantitative  variables,  according  to  variance  analysis  by
evine’s  test.  Odds  ratio  was  used  to  calculate  the  relative
easure  of  events  between  the  two  periods  of  study  and  95%
onﬁdence  interval  (95%  CI)  as  a  measure  of  the  precision  of
he  event  estimated.  Statistical  signiﬁcance  was  considered
hen  p  <  0.05.
Other  preventive  and  infection-reducing  strategies  have
een  continuously  performed  in  the  NICU  by  HICC  staff.  This
tudy  was  approved  by  the  Institutional  Review  Board  of
esearch  Ethics  Committee  of  UFMG.
esults
hroughout  the  study  period,  1229  at-risk  patients  were  fol-
owed,  totaling  26,260  patient  days.  A  total  of  367  patients
ad  583  episodes  of  HAI,  with  an  incidence  density  of  22.20
AI  episodes  per  1000  patient  days.  Table  1  shows  HAI
ncidence  density  per  birthweight  range,  with  a  signiﬁcant
eduction  in  infections  among  patients  ranging  from  2500  g
y  birthweight  range,  Neonatal  Intensive  Care  Unit,  HC/UFMG,
eriod  2  p  OR  95%  CI
013--2014)
7.3  0.945  0.98  0.50--1.90
2.25  0.424  1.18  0.78--1.80
0.15  0.757  0.94  0.62--1.41
1.62  0.025  1.38  1.04--1.82
8.01  0.389  1.14  0.84--1.54
0.50  0.044  1.18  1.00--1.39
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Table  2  Frequency  of  microorganisms  isolated  in  healthcare-associated  infections  by  patient  at-risk,  Neonatal  Intensive  Care
Unit, HC/UFMG,  2011--2014.
Microorganism  Total  Period  1  Period  2  p  OR  95%  CI
2011--2014 2011--2012  2013--2014
n (%)  n  (%)  n  (%)
Coagulase  negative  Staphylococcus  117  (9.52)  40  (7.37)  77  (11.22)  0.028  0.63  0.41--0.95
Staphylococcus  aureus  42  (3.42)  27  (4.97)  15  (2.19)  0.012  2.34  1.18--4.67
8.66
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Fungi 14  (1.14)  6  (
to  1501  g  during  Period  2.  There  was  signiﬁcant  reduction  in
the  total  number  of  reported  infections  (p  =  0.044;  OR:  1.18;
95%  CI  1--1.39)  (Table  1).
A  total  of  296  (54.81%)  and  355  (52.98%)  of  patients  at  risk
during  Period  1  and  Period  2  were  male,  respectively.  There
was  no  statistical  difference  in  regards  to  gender  (p  =  0.564;
OR:  1.08;  95%  CI  0.85--1.36),  but  19  newborns  had  no  deﬁned
gender.
The  cumulative  incidence  of  HAI  was  47.44%  of  at-risk
patients,  with  a  signiﬁcant  reduction  from  the  ﬁrst  to  the
second  study  period:  from  53.8%  to  42.4%  (p  <  0.001).
Considering  device-associated  infections,  there  was  no
signiﬁcant  difference  in  the  incidence  density  of  infections
by  device-day  between  the  two  periods  of  study.  Density  of
CVC-associated  bloodstream  infection  was  17.29  infections
per  1000  CVC  days  and  varied  from  15.39  to  19.09  (p  =  0.117;
OR:  0.81;  95%  CI  0.62--1.06).  Density  of  ventilator-associated
pneumonia  was  1.93  infections  per  1000  MV  days  and  varied
from  2.09  to  1.79  (p  =  0.789;  OR:  1.17;  95%  CI  0.38--3.62).
Density  of  IUC-associated  urinary  tract  infection  was  6.05
per  1000  IUC  days  and  varied  from  8.46  to  4.33  (p  =  0.243;
OR:  1.96;  95%  CI  0.62--6.16).
Frequency  of  episodes  of  HAI  treated  with  both  antibi-
otics  was  compared  between  the  two  periods  and  the
implementation  of  the  new  protocol  was  considered  effec-
tive.  There  was  a  signiﬁcant  decrease  in  the  use  of
vancomycin,  from  175  to  97  episodes  of  HAI  treated  with
vancomycin  (p  <  0.001;  OR:  1.98;  95%  CI  1.52--2.60),  and
there  was  a  signiﬁcant  increase  from  30  to  132  episodes  of
late  HAI  treated  with  oxacillin  (p  <  0.001;  OR:  4.68;  95%  CI
3.07--7.17).
Considering  the  frequency  of  microorganisms  isolated  in
cases  of  HAI  in  at-risk  patients,  there  was  a  signiﬁcant  reduc-
tion  in  HAI  due  to  S.  aureus  when  oxacillin  was  part  of  the
initial  empiric  regimen  (p  =  0.012),  and  an  increase  in  HAI
due  to  CoNS  (p  =  0.028),  but  no  signiﬁcant  changes  were
observed  in  the  ratio  of  gram-negative  bacteria  or  fungi
(Table  2).  All  S.  aureus  isolated  from  patient  samples  with
HAI  associated  infections  in  Period  1  were  oxacillin  sensi-
tive.  During  Period  2,  only  one  sample  presented  an  oxacillin
resistance  proﬁle  at  sensitivity  test.  This  reveals  that  the
prevalence  of  oxacillin-resistant  S.  aureus  at  this  NICU  was
calculated  as  2.4%  (n  =  1/42).
Table  3  shows  HAI  by  topography,  considering  S.  aureus
and  CoNS  associated  infections.  No  infections  with  major
organ  system  involvement,  such  as  endocarditis,  lower  respi-
ratory  tract  infection,  or  central  nervous  system  infection
with  isolation  of  S.  aureus, were  noted  in  Period  2;  only
conjunctivitis,  skin  infection,  and  bloodstream  infection  by
this  microorganism  were  reported.
p
s
t)  44  (6.41)  0.167  1.38  0.88--2.17
)  8  (1.17)  0.865  0.95  0.27--3.13
Mortality  and  lethality  were  calculated  by  comparing
ases  of  death  due  to  HAI  caused  by  S.  aureus  or  CoNS
etween  the  two  periods  (Table  4).  Mortality  was  consid-
red  to  be  the  number  of  deaths  associated  with  these
nfections  per  total  number  of  deaths.  Lethality  was  con-
idered  to  be  the  number  of  deaths  associated  with  these
nfections  per  total  number  of  cases  of  HAI  by  each  microor-
anism.  There  were  no  signiﬁcant  changes,  but  there  was
nly  one  death  associated  with  S.  aureus  during  Period  2
when  empiric  therapy  included  oxacillin),  compared  to  ﬁve
eaths  in  Period  1.  No  statistical  difference  was  observed  in
ortality  associated  with  CoNS  infection,  with  fewer  asso-
iated  deaths.
Morbidity  was  also  evaluated  considering  the  duration  of
ntimicrobial  treatment.  There  was  a  signiﬁcant  reduction
n  duration  of  treatment  with  oxacillin  in  Period  2  with  the
edian  time  reducing  from  11.5  to  6  days  (p  <  0.001).  Dura-
ion  of  treatment  with  vancomycin  increased  by  just  one
ay,  ranging  from  eight  days  in  Period  1  to  nine  days  in  Period
 (p  =  0.046).
iscussion
fter  the  introduction  of  empiric  treatment  with  oxacillin
n  the  therapeutic  regimen  for  late-onset  sepsis,  a  signiﬁ-
ant  reduction  in  cases  of  HAI  caused  by  S.  aureus  sensitive
o  oxacillin  (p  =  0.012)  was  observed.  The  incidence  density
f  infections  also  signiﬁcantly  decreased,  and  it  was  mainly
vident  in  patients  with  weight  ranging  from  1501  to  2500  g.
 previous  study17 already  showed  a  greater  number  of
atients  in  this  weight  range  at  risk  for  laboratory-conﬁrmed
loodstream  infections,  probably  due  to  the  proﬁle  of  this
ICU,  as  it  is  a center  of  fetal  medicine.  These  patients  have
rolonged  hospitalizations  and  they  are  at  risk  of  requiring
urgery,  CVC,  and  MV  that  may  increase  risk  of  infection.
Despite  the  increase  in  cases  of  infection  associated  with
oNS,  no  increase  in  mortality  and  evaluated  morbidity  was
bserved,  indicating  that  this  microorganism  can  be  con-
idered  less  pathogenic  and  presents  insidious  progression
hen  compared  to  S.  aureus  as  reported  in  literature.1,2,12
It  also  should  be  pointed  out  that  CoNS  infection  may
e  questioned  and  diagnostic  criteria  require  at  least  two
lood  cultures  with  the  same  microorganism.7,15 In  addi-
ion,  other  studies  demonstrate  that  it  is  possible  to  follow
linical  outcomes,  wait  for  culture  results,  and  also  post-
one  administration  of  antimicrobial  agents  in  patients  with
uspected  CoNS  infection.9--11,18
After  modiﬁcation  of  the  empiric  treatment  regimen
o  include  the  use  of  oxacillin,  there  was  an  increase  in
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Table  3  Healthcare-associated  infections  by  S.  aureus  and  coagulase  negative  Staphylococcus  (CoNS)  by  topography,  Neonatal
Intensive Care  Unit,  HC/UFMG,  2011--2014.
Topography  Microorganism  Period  1  Period  2  p  OR  95%  CI
n (%) n  (%)
Conjuntivitis CoNS  5  (38.5)  2  (22.2)  0.648  2.19  0.23--20.0
S. aureus  3  (23.1)  2  (22.2)  1  1.05  0.10--12.44
Endocarditis CoNS --  --  --  --  --
S. aureus  3  (100)  0  --  --  --
Necrotizing enterocolitis CoNS  --  1  (6.7)  --  --  --
S. aureus  --  0  --  --  --
Intra-abdominal  infection CoNS  -- 1  (50)  --  --  --
S. aureus -- 0  -- -- --
Vascular infection CoNS  -- 3  (100) -- -- --
S. aureus  --  0  --  --  --
Skin or  soft  tissue  infection CoNS  0  2  (3.2)  --  --  --
S. aureus 1  (2.0)  1  (1.6)  1  1.22  0.0--20.0
Bronchial or  tracheal  infection CoNS  0  --  --  --  --
S. aureus 1  (50.0) --  --  --  --
Pneumonia CoNS 0  --  --  --  --
S. aureus 1  (8.3) -- --  --  --
Urinary tract  infection CoNS  1  (7.1)  2  (13.3)  1  0.5  0.02--8.61
S. aureus 0  0  --  --  --
Central nervous  system  infection CoNS  0  2  (28.6)  --  --  --
S. aureus 3  (15.8) 0  --  --  --
Bloodstream  infection  (sepsis) CoNS  34  (21.38) 64  (38.1) 0.001  0.44  0.26--0.74
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oNS-associated  infections.  However,  no  statistical  dif-
erences  in  percentages  of  infection  associated  with
ram-negative  bacteria  and  fungi  were  detected.  It  was
onsidered  that  there  was  no  negative  interference  in
ora  proﬁle  and,  consequently,  to  patient  exposure  pro-
le.  Furthermore,  an  overall  statistical  reduction  of  HAI  was
chieved.  It  should  be  emphasized  that  a  smaller  number  of
nfections  is  directly  related  to  lower  use  of  antimicrobial
gents.  As  reported  by  Pinto  et  al.,6 criteria  to  reduce  sepsis
ncluded  signiﬁcantly  decreasing  the  use  of  vancomycin  and
u
s
a
Table  4  Mortality  and  lethality  of  patients  with  Staphylococcus  
Unit, HC/UFMG,  2011--2014.
Mortality/lethality  Total  
2011--2014 
n (%)  
General  mortality
Coagulase  negative  Staphylococcus/patient
at  risk
3  (0.24)  1
Staphylococcus  aureus/patient  at  risk  6  (0.49)  5
Lethality associated  to  coagulase  negative  Staphylococcus
Coagulase  negative  Staphylococcus/total  of
infections
3  (0.82)  1
S. coagulase  negative/total  of  infections  by
agent
3  (2.56)  1
Lethality associated  to  Staphylococcus  aureus
S. aureus/total  of  infections  6  (1.63)  5
S. aureus/total  of  infections  by  agent  6  (14.29)  5.4%) 12  (7.1) 0.58 1.34 0.58--3.20
arbapenem  as  well  as  the  number  of  antimicrobial  agents
sed,  although  those  authors  did  not  present  a  ﬂora  proﬁle.
As  published  in  other  reports,9,11 the  present  study
evealed  that  empiric  treatment  with  oxacillin  even  signif-
cantly  reduced  the  duration  of  treatment  (p  <  0.001),  in
ore  than  50%  of  days,  with  increase  in  only  one  day  of
ancomycin  in  Period  2.  The  reduction  in  days  of  oxacillin
se  can  likely  be  associated  with  the  appropriate  empiric  or
peciﬁc  use,  since  oxacillin  has  better  antimicrobial  activity
nd  therapeutic  efﬁcacy  in  sensitive  S.  aureus  infections.
spp.  hospital-associated  infections,  Neonatal  Intensive  Care
Period  1  Period  2  p  OR  95%  CI
2011--2012  2013--2014
n  (%)  n  (%)
 (0.18)  2  (0.29)  0.63  0.63  0.06--6.95
 (0.92)  1  (0.15)  0.08  6.32  0.74--53.91
 (0.56)  2  (1.07)  1  0.52  0.02--7.32
 (2.5)  2  (2.6)  1  0.96  0--14.16
 (2.78)  1  (0.53)  0.116  5.31  0.6--20.0
 (18.52)  1  (6.67)  0.395  3.18  0.3--30.0
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cEmpirical  therapy  for  neonatal  late-onset  sepsis  
It  is  important  to  highlight  that  S.  aureus  has  an  oxacillin-
sensitive  proﬁle  in  the  present  NICU,  supporting  the  change
of  empiric  therapy.
In  a  national  study  by  Bentlin  et  al.,19 which  investi-
gated  practices  related  to  prevalence  of  late-onset  sepsis
in  premature  infants,  the  authors  noted  that  centers  using
empiric  therapy  with  oxacillin  and  aminoglycosides  have  a
lower  incidence  of  late-onset  sepsis,  probably  due  to  more
effective  treatment.
Considering  the  recommendation  of  isoxazolyl  peni-
cillins  associated  with  gentamicin  as  empiric  treatment  for
late-onset  neonatal  sepsis,  a  study  by  Chiu  et  al.9 also
showed  a  signiﬁcant  reduction  in  the  use  of  vancomycin
and  increased  use  of  oxacillin  without  signiﬁcant  difference
in  neonatal  morbidity  and  mortality  as  assessed  by  inci-
dence  of  late-onset  sepsis,  meningitis,  and  deaths.  However,
those  authors  did  not  compare  patients  with  laboratory-
conﬁrmed  S.  aureus  and  CoNS-associated  HAI  as  in  this
study,  which  showed  a  signiﬁcant  reduction  in  episodes  S.
aureus-associated  infections,  with  as  well  as  fewer  cases
of  infections  with  major  organ  system  involvement  such  as
endocarditis,  lower  respiratory  tract  infection,  and  central
nervous  system  infection.
In addition  to  a  statistical  reduction  in  the  overall  num-
ber  of  HAI  cases  as  well  as  HAI  due  to  susceptible  S.
aureus,  fewer  infections  with  major  organ  system  involve-
ment  were  also  observed,  reduced  mortality  associated  with
this  microorganism  was  noted,  and  a  signiﬁcant  reduction  in
days  of  treatment  duration  and  hospitalization  was  demon-
strated.  These  ﬁndings  can  be  considered  adequate  to  avoid
morbidity  associated  with  sepsis  and  exposure  to  other
adverse  events.  As  reported  by  Kaufman,20 accuracy  in  diag-
nosis  and  reduction  of  the  use  of  antimicrobial  agents  are
important  to  prevent  infections  in  general  and,  speciﬁcally,
neonatal  mortality  related  to  sepsis.
A  multicenter  study  with  348  NICUs11 evaluated  imme-
diate  use  of  vancomycin  (<1  day)  and  delayed  use  (1--3
days)  in  the  ﬁrst  episode  of  late-onset  sepsis  associated  with
CoNS.  The  authors  reported  that  there  was  no  difference
in  the  rates  of  mortality  at  7  or  30  days  after  the  initi-
ation  of  treatment  or  at  discharge.  Furthermore,  patients
who  started  the  use  of  vancomycin  immediately  had  a  sig-
niﬁcantly  longer  duration  of  treatment,  with  a  median  of
two  additional  days.  In  another  multicenter  study  conducted
by  the  same  group,18 there  was  no  difference  in  mortal-
ity  when  comparing  the  newborns  with  possible,  probable
or  conﬁrmed  infection  by  CoNS.  Additionally,  the  authors
reported  that  patients  with  infections  associated  with  CoNS
had  signiﬁcantly  lower  mortality  than  patients  with  nega-
tive  blood  cultures,  considering  that  higher  mortality  could
be  attributed  to  other  microorganisms  not  isolated  in  blood
cultures.  It  must  be  considered  that  an  antimicrobial  agent
may  be  used  unnecessarily,  as  possible  or  probable  infections
by  CoNS  are  overestimated.
Cotten  et  al.,21 in  a  multicenter  cohort,  found  in  a  mul-
tivariate  analysis  that  prolonged  duration  of  initial  therapy
in  days  was  associated  with  death  of  extremely  low  birth
weight  infants,  especially  when  treatment  with  antimicro-
bial  agents  exceeded  ﬁve  days,  with  increased  odds  per  day
of  antimicrobial  use.  It  must  also  be  considered  that  mortal-
ity  increases  when  empiric  therapy  is  inadequate,  a  factor
which  can  increase  treatment  duration.
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A  previous  study  in  the  same  NICU  revealed  high  mortality
f  patients  with  sepsis  with  reported  laboratory-conﬁrmed
.  aureus.5 In  this  study,  a  reduction  in  the  frequency  of
eaths  due  to  S.  aureus-associated  HAI  from  Period  1  (ﬁve
eaths)  to  Period  2  (one  death)  was  noted.  This  reduction
ended  toward  signiﬁcance  (p  =  0.08).  The  only  death  asso-
iated  with  S.  aureus  in  Period  2  was  that  of  a patient  with
everal  malformations  and  potential  trisomy  13.  Due  to  the
linical  severity  of  the  patient’s  condition,  tests  were  per-
ormed  to  screen  for  infection.  However,  treatment  with
xacillin  was  initiated  when  the  blood  culture  results  were
vailable,  two  days  after  testing.  The  death  may  be  associ-
ted  with  the  underlying  disease  and  delay  in  the  use  of  an
ppropriate  antimicrobial  agent.
The  present  study  identiﬁed  just  one  and  two  cases  of
eath  due  to  CoNS-associated  HAI,  respectively,  in  Periods
 and  2,  without  statistical  signiﬁcance.  Literature  also  dis-
loses  that  mortality  associated  with  infection  by  CoNS  is
elated  to  1%  of  cases.5,10 Karlowicz  et  al.10 investigated
auses  of  fulminant  late-onset  sepsis  and  observed  that
ven  when  cases  of  CoNS  infection  were  associated  with
eath,  patients  had  other  comorbidities  or  cultures  grew
ore  than  one  microorganism,  suggesting  contamination.
akhoul  et  al.8 assessed  risk  factors  for  early  mortality  after
ate-onset  neonatal  sepsis  and  they  reported  that  patients
ith  infections  caused  by  CoNS  had  a  lower  risk  of  death
hen  compared  to  patients  with  infections  caused  by  other
icroorganisms.
In  a  study  by  Hemels  et  al.,13 cefazolin  associated  with
entamicin  was  used  as  empiric  treatment  for  late-onset
eonatal  sepsis  due  to  CoNS.  Clinical  response  was  observed
n  87%  of  treated  patients  and  sensitivity  to  cefazolin  was
bserved  in  88%  of  the  strains  analyzed.  No  difference
n  length  of  stay  (0.77  days)  or  mortality  (p  =  0.33)  was
bserved  among  treated  patients  with  sepsis  due  to  sensi-
ive  or  resistant  strains  of  CoNS.  Those  authors  suggest  that
ther  beta-lactam  antibiotics  may  be  useful  in  the  treat-
ent  of  HAI  in  newborn  infants,  decreasing  the  need  for  the
se  of  vancomycin.
Considering  rational  use  of  antibiotics,  vancomycin  use
hould  be  restricted  in  units  with  high  prevalence  of  S.
ureus  resistant  to  vancomycin,  in  cases  without  clinical
r  laboratory  response  within  48--72  h  despite  use  of  a
eta-lactam  such  as  oxacillin,  and  deﬁned  cases  of  CoNS
esistant  to  oxacillin  without  clinical  response  and  which
s  not  considered  to  be  commensal.1,22 These  recommen-
ations  follow  the  guidelines  of  the  Centers  for  Disease
ontrol  and  Prevention,  in  order  to  avoid  signiﬁcant  increase
n  strains  of  Enterococcus  spp.  and  other  bacteria  resistant
o  vancomycin.23 The  restriction  of  utilization  of  antimi-
robial  agents  based  on  stewardship  is  important  to  reduce
nterference  in  microbiome,  selection  of  resistant  microor-
anisms  and  atopic  manifestations,  and  other  complications
n  premature  infants,  such  as  enterocolitis  and  death.24
In  conclusion,  the  present  study  showed  that  there  was
o  worsening  of  outcomes  in  newborns  when  using  an
nti-staphylococcal  beta  lactam  to  treat  late-onset  sepsis,
onsidering  that  rates  of  mortality  and  morbidity  associated
ith  CoNS  infections  did  not  increase  and  that  there  was  also
n  improvement  of  rates  of  S.  aureus  associated  infections.
hus,  antimicrobial  stewardship  with  use  of  oxacillin  may
e  recommended  in  late-onset  neonatal  sepsis,  according
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278  
o  the  epidemiological  proﬁle  of  each  NICU,  which  must
e  associated  with  other  effective  infection  prevention
ractices,  in  order  to  avoid  the  use  of  broad-spectrum
ntimicrobial  agents.
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